MINERALYS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.2 USD | -0.25% |
|
-6.15% | +41.86% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 353.5 | 605.7 | - | - |
| Enterprise Value (EV) 1 | 353.5 | 500.2 | 468.6 | 468.7 |
| P/E ratio | -4.32 x | -4.07 x | -3.81 x | -3.6 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -4.18 x | -3.38 x | -2.51 x | -2.12 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 41,105 | 49,649 | - | - |
| Reference price 2 | 8.600 | 12.20 | 12.20 | 12.20 |
| Announcement Date | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | - | -31.48 | -84.66 | -147.8 | -186.5 | -221.4 |
| EBIT 1 | - | -31.48 | -84.66 | -150.3 | -178.1 | -201.8 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -29.8 | -71.9 | -143.7 | -163.7 | -192 |
| Net income 1 | -19.41 | -29.8 | -71.9 | -142 | -173.2 | -192 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.3600 | -5.770 | -1.990 | -2.996 | -3.205 | -3.387 |
| Free Cash Flow | - | -29.22 | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 23-01-18 | 23-03-15 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | -14.94 | -15.74 | -26.27 | -27.71 | -35.36 | -37.14 | -38.45 | -40.53 |
| EBIT 1 | -10.01 | -14.94 | -15.74 | -26.27 | -27.71 | -35.36 | -36.07 | -39.18 | -39.84 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.073 | -12.61 | -12.14 | -22.76 | -24.39 | -31.51 | -34.85 | -39.78 | -41.52 |
| Net income 1 | -9.073 | -12.61 | -12.14 | -22.76 | -24.39 | -31.51 | -34.75 | -38.26 | -39.58 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.740 | -0.5100 | -0.3100 | -0.5700 | -0.6100 | -0.7000 | -0.7140 | -0.7660 | -0.7720 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 23-03-15 | 23-05-15 | 23-08-07 | 23-11-07 | 24-03-21 | 24-05-09 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 105 | 137 | 137 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -29.2 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -76.1% | -58.2% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | -8.140 | - | - | - | - |
| Cash Flow per Share 2 | - | -5.660 | -2.240 | -2.670 | -3.220 | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 23-01-18 | 23-03-15 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.2
USD
Average target price
33.5
USD
Spread / Average Target
+174.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.86% | 607M | |
| +67.53% | 62.86B | |
| -0.77% | 41.38B | |
| +45.66% | 40.38B | |
| -10.72% | 27.64B | |
| +13.30% | 26.46B | |
| -22.79% | 18.9B | |
| +4.70% | 12.67B | |
| +24.10% | 12.27B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- MLYS Stock
- Financials Mineralys Therapeutics, Inc.
